umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Anti-human SIRP antibody is a new tool for cancer immunotherapy
Show others and affiliations
2018 (English)In: Cancer Science, ISSN 1347-9032, E-ISSN 1349-7006, Vol. 109, no 5, p. 1300-1308Article in journal (Refereed) Published
Abstract [en]

Interaction of signal regulatory protein (SIRP) expressed on the surface of macrophages with its ligand CD47 expressed on target cells negatively regulates phagocytosis of the latter cells by the former. We recently showed that blocking Abs to mouse SIRP enhanced both the Ab-dependent cellular phagocytosis (ADCP) activity of mouse macrophages for Burkitt's lymphoma Raji cells opsonized with an Ab to CD20 (rituximab) invitro as well as the inhibitory effect of rituximab on the growth of tumors formed by Raji cells in nonobese diabetic (NOD)/SCID mice. However, the effects of blocking Abs to human SIRP in preclinical cancer models have remained unclear given that such Abs have failed to interact with endogenous SIRP expressed on macrophages of immunodeficient mice. With the use of Rag2(c)(-/-)(-/-) mice harboring a transgene for human SIRP under the control of human regulatory elements (hSIRP-DKO mice), we here show that a blocking Ab to human SIRP significantly enhanced the ADCP activity of macrophages derived from these mice for human cancer cells. The anti-human SIRP Ab also markedly enhanced the inhibitory effect of rituximab on the growth of tumors formed by Raji cells in hSIRP-DKO mice. Our results thus suggest that the combination of Abs to human SIRP with therapeutic Abs specific for tumor antigens warrants further investigation for potential application to cancer immunotherapy. In addition, humanized mice, such as hSIRP-DKO mice, should prove useful for validation of the antitumor effects of checkpoint inhibitors before testing in clinical trials.

Place, publisher, year, edition, pages
WILEY , 2018. Vol. 109, no 5, p. 1300-1308
Keywords [en]
antibody, CD47, macrophage, phagocytosis, signal regulatory protein
National Category
Immunology in the medical area
Identifiers
URN: urn:nbn:se:umu:diva-150702DOI: 10.1111/cas.13548ISI: 000434071400003PubMedID: 29473266OAI: oai:DiVA.org:umu-150702DiVA, id: diva2:1245484
Available from: 2018-09-05 Created: 2018-09-05 Last updated: 2018-09-05Bibliographically approved

Open Access in DiVA

fulltext(1064 kB)64 downloads
File information
File name FULLTEXT01.pdfFile size 1064 kBChecksum SHA-512
fe08a90875eb5a151f9dc119c312b7c7884a0c075c7e38758fcdd75018ce2849d874760ebacdb2097833c77733c4a38c11846cf47c3eb50a27d217b982c44b45
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Oldenborg, Per-Arne

Search in DiVA

By author/editor
Murata, YojiOldenborg, Per-Arne
By organisation
Histology and Cell Biology
In the same journal
Cancer Science
Immunology in the medical area

Search outside of DiVA

GoogleGoogle Scholar
Total: 64 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 129 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf